SYSTEMATIC STUDY OF THREE TYPES OF GLYCOSYLTRANSFERASES

近年来，一些糖基转移酶发挥作用的可能性 肿瘤标志物已经变得明显起来。在这个节目中，我们集中精力 我们在研究人类岩藻糖基、半乳糖和 唾液酸转移酶。我们并不打算将它们逐一净化 半乳糖基转移酶以外的糖基转移酶。更多的强调将 借助于对这些酶的专一性研究 从糖共轭中获得的低聚糖和适当的受体。一个 节目所需的各种合成接受者已经成为 在我们的实验室可以买到。这些调查应该会导致 发现一种特定类型的高度特异性受体 糖基转移酶。利用这个特定的接受者，水平 健康人和健康人血清中糖基转移酶的活性 将对从卵巢癌患者身上获得的样本进行检查。事实上, 我们已经有效地利用合成化合物作为受体 几种酶。改良的测定方法，用于测定乳酸菌中的某些酶 我们实验室已经开展了拟议的调查工作。这个 从糖核苷酸到受体的糖苷键，由 糖基转移酶的催化反应将由不同的 程序。鉴定所需的某些特定糖苷酶 在我们的实验室里就能找到这种连锁反应。 在这个项目中，我们不仅仅是建议重复这些研究 其他研究人员报告的三个糖基转移酶系统，但 而是试图解决现有的混乱和差异 将这些酶视为肿瘤标记物。准确地说，我们正在提议 采用系统的方法对这三种生物化学进行研究 糖基转移酶的类型。我们的临床研究是有限的 仅涉及使用卵巢癌患者的样本。(1)

In recent years, the possibility of some glycosyltransferases acting as tumor markers has become apparent. In this program we are concentrating our efforts on the study of human fucosyl, galactosyl, and sialytransferases. We do not intend to purify each of these glycosyltransferases other than galactosyltransferase. Much emphasis will be placed on the specificity studies of these enzymes with the aid of oligosaccharides and appropriate acceptors obtained from glycoconjugates. A variety of synthetic acceptors required for the program have already become available in our laboratory. These investigations should lead to the discovery of a highly specific acceptor for a specific type of glycosyltransferase. Utilizing this specific acceptor, levels of glycosyltransferase activity in the sera of healthy individuals and in specimens obtained from ovarian cancer patients will be examined. In fact, we have already made effective use of synthetic compounds as acceptors for several enzymes. Modified assay procedures for certain enzymes in the proposed investigations have been developed in our laboratory. The glycosidic linkage from a sugar nucleotide to the acceptor formed by the catalytic reaction of a glycosyltransferase will be established by various procedures. Some specific glycosidases required for the characterization of this linkage are available in our laboratory. In this program, we do not merely propose to duplicate the studies of these three glycosyltransferase systems as reported by other investigators, but rather to attempt to resolve the existing confusion and discrepancies regarding these enzymes as tumor markers. Precisely, we are proposing to undertake a systematic approach for the biochemical studies of these three types of glycosyltransferases. Our clinical studies are limited and involve the use of specimens from only ovarian cancer patients. (1)